Welcome to Flow Pharma Inc.

Page Loading...

Menu
blob-1
blob-2

Dr. Tunde Otulana Joining Flow Pharma, Inc. Board of Directors

Tunde Otulana, M.D. is a former FDA Medical Officer and has held multiple senior positions in the pharmaceutical industry, including at Boehringer Ingelheim, Mallinckrodt, and Veloxis, where he now serves as Chief Medical Officer.

PLEASANT HILL, CA / ACCESSWIRE / February 23, 2021 / Flow Pharma, Inc., a San Francisco Bay Area biotechnology company developing the FlowVax(TM) peptide vaccine platform technology, today announced that Tunde Otulana, M.D. has joined the Company’s Corporate Board. Dr. Otulana served as Medical Officer and Clinical Team Leader in the Pulmonary & Allergy Drug Products Division at the United States Food and Drug Administration (FDA) from 1991 to 1997. After leaving the FDA, he served in various positions of increasing responsibility in the biotech and pharmaceutical industries, including Senior Vice President for Clinical Development and Medical Affairs at Boehringer Ingelheim and Senior Vice President and Chief Medical Officer at Mallinckrodt. He is currently the Chief Medical Officer at Veloxis Pharmaceuticals.

Dr. Otulana is a Clinical Professor of Pulmonary and Critical Care Medicine at the University of California, Davis Medical School as a member of the Volunteer Clinical Faculty. He also serves as a Non-Executive Director on the Research, Education and Innovation Board of Children’s National Hospital, Washington DC.

Dr. Otulana will be taking over the seat vacated by Mr. Jack Lloyd, who has recently retired from the Board. Sitting board member, Dr. Tikoes Blankenberg, will be assuming Mr. Lloyd’s former Chairman role.

“We are delighted that Dr. Otulana has joined our Board,” said Reid Rubsamen, M.D., CEO, Flow Pharma, Inc. “Dr. Otulana has extensive experience as a senior officer in the pharmaceutical industry, and we look forward to working closely with him. His clinical and regulatory expertise in Pulmonary Medicine is especially relevant to our ongoing development of our FLOVID-20 therapy for COVID-19 and our FlowVax Marburg vaccine for Marburg, a weaponized version of Ebola, both designed for delivery by inhalation.”

“I am very pleased to be working with Flow Pharma and look forward to helping them as they move forward using their platform technology to develop vaccines and therapies for emerging viral threats and for cancer,” said Tunde Otulana, M.D.

About Flow Pharma

Flow Pharma, Inc. is currently manufacturing FLOVID-20(TM) for planned clinical testing. FLOVID-20 is an inhaled Targeted T-cell Immunotherapy for COVID-19 being developed for patients recently exposed to SARS-CoV-2 who are at risk of developing the COVID-19 disease. Flow Pharma is also developing FlowVax Marburg, an inhaled vaccine for Marburg Virus, under contract with the United States Department of Defense. Flow Pharma’s Targeted Immunotherapy Pipeline also includes FlowVax BreastCA being developed as neoadjuvant therapy for triple-negative breast cancer.

Forward-Looking Statements

This press release may contain forward-looking statements, including information about management’s view of Flow Pharma, Inc. (“the Company”), future expectations, plans, and prospects. In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this presentation other than those of historical fact about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other factors, which may cause the results of the Company, its subsidiaries, and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this presentation are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance, or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Flow Pharma, Inc.

Media Contact

Flow Pharma, Inc.

3451 Vincent Road

Pleasant Hill, California 94523

[email protected]

SOURCE: Flow Pharma, Inc.

View source version on accesswire.com: 

https://www.accesswire.com/631171/Dr-Tunde-Otulana-Joining-Flow-Pharma-Inc-Board-of-Directors

on apnews.com:

https://apnews.com/press-release/accesswire/technology-business-public-health-corporate-news-diseases-and-conditions-e06ed9c66630e233e86e39c63f2c1090

Strategic Vaccines, LLC today announced that Lockheed Martin will conduct a computational study of the Strategic Vaccines’ proprietary manufacturing systems designed to address emerging viral threats, beginning with COVID-19.

These proprietary Test and Go Rapid Deployment (TANGO-RDP) manufacturing systems will be housed at the Texas A&M Center for Innovation in Advanced Development and Manufacturing (Texas A&M CIADM) at College Station.

“Strategic Vaccines is manufacturing FLOVID-20, an inhaled treatment for COVID-19 designed to keep patients out of the hospital,” said Reid Rubsamen, M.D., CEO, Strategic Vaccines, LLC. “The TANGO-RDP manufacturing systems we’ll establish at the Texas A&M CIADMsite will enable us to quickly address emerging viral threats. Lockheed Martin has a unique skill set matching our requirements and is helping us with that process.”

Flow Pharma, Inc. has formed a joint venture, Strategic Vaccines LLC, and today announced that this new joint venture has entered into a public-private collaboration between Strategic Vaccines LLC, and Texas A&M University Center for Innovation in Advanced Development and Manufacturing (CIADM) in College Station, Texas to work together on addressing emerging viral threats.

After successfully completing STTR Phase I funded design of a Marburg virus prophylactic countermeasure vaccine, Flow Pharma has received a follow-on Phase II STTR contract award to transition into vaccine manufacturing and pre-clinical testing.

Flow Pharma today announced that the Company has received a Phase II STTR contract award to continue developing a protective vaccine against Marburg virus. This award follows Flow Pharma successfully completing the Phase I STTR contract from the United States Department of Defense for the same project. Flow Pharma is working in collaboration with Dr. Trevor Brasel and his team at the University of Texas Medical Branch (UTMB) in Galveston, Texas.

Chemical and Biological Defense Program Small Business Innovation Research Logo

“We are happy to be working with Flow Pharma on the pre-clinical testing phase of their FlowVax Marburg development program. Our team has extensive experience working with Marburg virus and similar viruses like Ebola in various pre-clinical models. We are very fortunate at UTMB in that we have access to unique BSL-4 laboratories, including the Galveston National Laboratory and the Robert E. Shope, MD, Laboratory, that allow us to conduct studies like these safely and at a high level of quality to ensure data integrity for sponsors like Flow Pharma,” said Trevor Brasel, Ph.D., M(ASCP)CM, Assistant Professor, Department of Microbiology and Immunology, UTMB.

Chairman of Rising Tide Fund Ossama Hassanien from SF and Menlo Park visits our HQ
Chairman of Rising Tide Fund Ossama Hassanien from SF and Menlo Park visits our HQ

The peer reviewed journal Vaccine has published the results of a mouse study demonstrating efficacy of the Company’s Ebola vaccine. The article describes how Flow Pharma used the same approach to design FLOVID-20 (FlowVax COVID-19), now undergoing pre-clinical testing for protection against SARS-CoV-2, the virus that causes COVID-19.

Flow Pharma today announced that an article entitled “An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design” describing work led by Flow Pharma scientists, was published today in the peer reviewed journal Vaccine, an Elsevier publication.

“Our article published today shows that a single injection of our Ebola vaccine provided 100% protection for mice exposed to Ebola virus” said Charles Herst, Ph.D., Chief Science Officer, Flow Pharma and first author on the article. “By relying on killer T-cells rather than antibodies, FlowVax Ebola is able to attack the nucleocapsid protein located at the center of the virus where antibodies cannot reach. We are taking the same approach with FlowVax COVID-19.”

“As a virologist interested in how the immune system reacts to viral infections, I think it is very interesting that people who previously survived Ebola and SARS-CoV-1 outbreaks were found to have killer T-cells targeting the nucleocapsid protein for those two different viruses” said Tom Hodge, Ph.D., former CDC Laboratory Director, now Flow Pharma Scientific Advisory Board member and article co-author. “Flow Pharma is now conducting pre-clinical testing for FlowVax COVID-19 which is designed to attack the nucleocapsid protein on SARS-CoV-2, the virus that causes COVID-19. By doing this we are trying to mimic the immune system response of the survivors of the SARS-CoV-1 outbreak in 2003.”

“Flow Pharma has been developing T-cell vaccines for immuno oncology and infectious disease applications using the FlowVax vaccine platform for over a decade” said Reid Rubsamen, M.D., CEO, Flow Pharma and co-author on the article. “We are happy to be using our FlowVax vaccine platform to address the new threat posed by SARS-CoV-2, the virus that causes COVID-19.”

Oakwood labs logo
flow pharma logo

Oakwood Laboratories in the Cleveland, Ohio area is a leader in microsphere-based pharmaceutical development and manufacturing. Oakwood will operate Flow Pharma’s production volume vaccine manufacturing system at their Solon, Ohio manufacturing plant, using Oakwood’s state-of-the-art microsphere-based processing, quality testing, and packaging systems to make GMP FLOVID-20 doses for clinical testing.

Oakwood Laboratories has for many years been a leader in controlled release, injectable microsphere-based pharmaceutical development and manufacturing. We are currently manufacturing multiple FDA approved sterile products in our GMP facility, designed specifically to manufacture microsphere-based products” said Mark Smith, President of Oakwood Labs. “We also have the analytical, Quality Control, and other quality systems and infrastructure in place to test this type of product. Since the vaccine does not make use of either live or attenuated virus, there is no risk of infection from processing it.”